Bill

Bill > A00895


NY A00895

NY A00895
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.


summary

Introduced
01/11/2023
In Committee
01/03/2024
Crossed Over
Passed
Dead
12/31/2024

Introduced Session

2023-2024 General Assembly

Bill Summary

AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs

AI Summary

This bill enacts the "Manufacturer Disclosure and Transparency Act," which requires pharmaceutical manufacturers doing business in New York to notify the state Attorney General within 30 days if they enter into an arrangement with another manufacturer that delays or prevents the introduction of a generic substitute drug. The Attorney General is then required to share this information with the state's Drug Utilization Review Board, Medicaid managed care plans, health carriers, and pharmacy benefits managers. The bill also authorizes the Attorney General to fine manufacturers for failing to properly notify the state as required.

Committee Categories

Business and Industry

Sponsors (26)

Last Action

referred to consumer affairs and protection (on 01/03/2024)

Bill Topics

Banking, Finance, and Domestic Commerce
  • ‐ Corporate Management
Health
  • ‐ Regulation of Drug Industry and Pharmacies

bill text


bill summary

Loading...

bill summary

Loading...
Loading...